Data Show Obagi Medical Products' Solubilized Benzoyl Peroxide Gel May Provide Dramatic Reductions in Acne Lesions Within Four Weeks

LONG BEACH, Calif.--(BUSINESS WIRE)--Oct 19, 2007 - Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today at the Fall Clinical Dermatology Conference in Las Vegas results from a pooled analysis of three randomized, investigator-blind trials evaluating solubilized benzoyl peroxide (BPO) for the treatment of acne that suggest monotherapy with solubilized 5 percent BPO (CLENZIderm M.D.(TM)) may provide dramatic reductions in acne lesions within 4 weeks.

In the analysis, reduction in inflammatory and non-inflammatory lesions was greater with the solubilized 5 percent BPO regimens than with the jar gel formulation of BPO/clindamycin. Additionally, patients reported greater overall satisfaction and comparable tolerability with the solubilized 5 percent BPO regimen.

The data, presented by James Q. Del Rosso, DO, Dermatology Residency Director Valley Hospital Medical Center and Las Vegas Skin & Cancer Clinics, Las Vegas, NV, were pooled from 112 patients and evaluated the use of solubilized 5 percent BPO alone, solubilized BPO gel + 2 percent salicylic acid +/- 2 percent salicylic acid cleanser, and a prescription BPO/clindamycin combination gel product.

The solubilized 5 percent BPO, a novel patent pending formulation developed exclusively for Obagi Medical Products, maximizes the bioavailability of BPO, the most widely used topical agent for acne, and enhances its penetration into follicles. The solubilized 5 percent BPO formulation tested is available only through physician's offices as part of CLENZIderm M.D., the Obagi Medical Products 3-step acne system, which includes a pore therapy and cleanser, both of which contain 2 percent salicylic acid.

"The CLENZIderm M.D. acne treatment system offers to dermatologists and their patients an option that has been proven to be effective and well tolerated in multiple clinical trials," said Dr. Del Rosso. "There is solid science supporting both the technology itself and the therapeutic benefits of this system. Additionally, there are two formulations of the system available that can be tailored to the needs of the individual patient based on their skin type."

The solubilized BPO regimens resulted in a 36 percent reduction in non-inflammatory lesions (BPO gel + cleanser +/- toner) and a 29 percent reduction in non-inflammatory lesions (BPO gel alone) vs. 28 percent (BPO/clindamycin) at week 2; and a 51 percent (BPO gel + cleanser +/- toner) and a 42 percent (BPO gel alone) reduction in non-inflammatory lesions vs. 28 percent (BPO/clindamycin) at week 4. Mean levels of stinging/burning, erythema, dryness and itching remained less than mild for all regimens at all time points.

"The clinical evaluations continue to bolster the data and reinforce the efficacy benefits of the Obagi CLENZIderm M.D. system," said Rick Kozloski, Vice President Marketing & Dermatology, Obagi Medical Products, Inc. "We are proud to offer a proven and trusted acne therapy that consistently provides both medical professionals and their patients a high level of efficacy and satisfaction."

Each treatment was applied once or twice daily for 2-4 weeks. Patients ranged from 11 to 45 years of age, with a mean age of 20 years, and were evaluated weekly. Patients were predominantly Caucasian with Fitzpatrick skin type III. Efficacy was based on a mean reduction in inflammatory and non-inflammatory lesion count. Tolerability was evaluated on severity of stinging/burning, erythema, dryness and itching. Patients reported high levels of satisfaction across all studies. Mean satisfaction scores in studies using the 3-part acne system were statistically significant following 1 week of treatment.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm, 1988; Obagi-C Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi Professional-C (a line of highly stable vitamin C serums), 2005; Obagi Nu-Derm Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm eye skin care and Obagi CLENZIderm M.D. acne therapeutic systems, 2007; and a formulation of CLENZIderm for normal to dry skin, July 2007. Obagi's products are only available through physicians. Visit www.obagi.com for information.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2006. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.

Contact

Media:
HealthSTAR Public Relations
Dave Schemelia
(o) 646-722-8819 / (c) 609-468-9325
Dschemelia@healthstarpr.com
or
Investors:
ICR, Inc.
Ina McGuinness/Lena Adams, 310-954-1100

Posted: October 2007

View comments

Hide
(web5)